Patents Assigned to Curemark, LLC
-
Publication number: 20120189703Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.Type: ApplicationFiled: February 28, 2012Publication date: July 26, 2012Applicant: Curemark LLCInventors: Joan M. FALLON, Matthew HEIL
-
Patent number: 8211661Abstract: A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration.Type: GrantFiled: June 19, 2009Date of Patent: July 3, 2012Assignee: Curemark, LLCInventor: Joan M. Fallon
-
Publication number: 20120114562Abstract: A method of utilizing the chymotrypsin level of an individual as a measure of the success of neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. A method for determining the efficacy of neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with neuropeptides, peptides, or digestive enzyme administration.Type: ApplicationFiled: December 7, 2011Publication date: May 10, 2012Applicant: CUREMARK, LLCInventor: Joan M. FALLON
-
Publication number: 20120114626Abstract: A method of utilizing the chymotrypsin level of an individual as a measure of the success of neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. A method for determining the efficacy of neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with neuropeptides, peptides, or digestive enzyme administration.Type: ApplicationFiled: December 7, 2011Publication date: May 10, 2012Applicant: CUREMARK, LLCInventor: Joan M. FALLON
-
Patent number: 8163278Abstract: A method of determining the efficacy of secretin, neuropeptides, peptides, and/or digestive enzymes for treatment of an individual diagnosed with a pervasive development disorder, such as autism, where the individual has an abnormal fecal chymotrypsin level and exhibits a lack of protein digestion. A sample of feces is obtained from the individual in order to determine a quantitative level of chymotrypsin in the sample. The quantitative level of chymotrypsin is used to determine the efficacy of treating the individual with secretin, neuropeptides, peptides, and/or digestive enzymes. If it is determined, based on the individual's fecal chymotrypsin level, that the individual would benefit from the administration of secretin, neuropeptides, peptides, and/or digestive enzymes, then the amount necessary to effect a change in the individual's autistic behavior is determined by the individual's fecal chymotrypsin level, age and weight.Type: GrantFiled: October 8, 2003Date of Patent: April 24, 2012Assignee: Curemark LLCInventor: Joan M. Fallon
-
Publication number: 20120070504Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.Type: ApplicationFiled: October 12, 2011Publication date: March 22, 2012Applicant: Curemark LLCInventor: Joan M. FALLON
-
Publication number: 20120027848Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.Type: ApplicationFiled: July 28, 2011Publication date: February 2, 2012Applicant: Curemark LLCInventors: Joan M. Fallon, Matthew Heil
-
Patent number: 8105584Abstract: A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration.Type: GrantFiled: September 8, 2008Date of Patent: January 31, 2012Assignee: Curemark LLCInventor: Joan M. Fallon
-
Publication number: 20120003628Abstract: Methods for aiding in the diagnosis of disorders including, but not limited to, PDDs (Pervasive Development Disorders), Dysautonomic disorders, Parkinson's disease and SIDS (Sudden Infant Death Syndrome). In one aspect, a diagnosis method comprises analyzing a stool sample of an individual for the presence of a biological marker (or marker compound) comprising one or more pathogens, which provides an indication of whether the individual has, or can develop, a disorder including, but not limited to, a PDD, Dysautonomia, Parkinsons disease and SIDS. Preferably, the presence of one or more pathogens is determined using a stool immunoassay to determine the presence of antigens in a stool sample, wherein such antigens are associated with one or more pathogens including, but not limited to, Giardia, Cryptosporidium, E. histolytica, C. difficile, Adenovirus, Rotavirus or H. pylori.Type: ApplicationFiled: August 12, 2011Publication date: January 5, 2012Applicant: CUREMARK LLCInventor: Joan M. Fallon
-
Publication number: 20120004192Abstract: A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.Type: ApplicationFiled: August 8, 2011Publication date: January 5, 2012Applicant: CUREMARK LLCInventors: Joan M. Fallon, Richard Feltenstein
-
Patent number: 8084025Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.Type: GrantFiled: April 20, 2009Date of Patent: December 27, 2011Assignee: Curemark LLCInventor: Joan M. Fallon
-
Patent number: 8030002Abstract: Methods for aiding in the diagnosis of disorders including, but not limited to, PDDs (Pervasive Development Disorders), Dysautonomic disorders, Parkinson's disease and SIDS (Sudden Infant Death Syndrome). In one aspect, a diagnosis method comprises analyzing a stool sample of an individual for the presence of a biological marker (or marker compound) comprising one or more pathogens, which provides an indication of whether the individual has, or can develop, a disorder including, but not limited to, a PDD, Dysautonomia, Parkinsons disease and SIDS. Preferably, the presence of one or more pathogens is determined using a stool immunoassay to determine the presence of antigens in a stool sample, wherein such antigens are associated with one or more pathogens including, but not limited to, Giardia, Cryptosporidium, E. histolytica, C. difficile, Adenovirus, Rotavirus or H. pylori.Type: GrantFiled: November 16, 2001Date of Patent: October 4, 2011Assignee: Curemark LLCInventor: Joan M. Fallon
-
Patent number: 8012710Abstract: A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder.Type: GrantFiled: June 19, 2009Date of Patent: September 6, 2011Assignee: Curemark, LLCInventor: Joan M. Fallon
-
Patent number: 8012930Abstract: A therapeutic method for treating an individual diagnosed with PDD pervasive developmental disorder comprises determining the efficacy of digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level. A method for reducing the amount of methylphenidate (Ritalin) being taken by an individual with attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) by administering a therapeutic amount of digestive enzymes is also provided.Type: GrantFiled: March 11, 2008Date of Patent: September 6, 2011Assignee: Curemark, LLCInventor: Joan M. Fallon
-
Patent number: 8008036Abstract: A method for confirming a diagnosis of autism in an individual comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and comparing the quantitative level of fecal chymotrypsin in the stool sample of the person having autism to a stool sample from an individual that has a normal fecal chymotrypsin level and does not have autism and confirming a diagnosis of autism based on the measurement of the quantitative level of fecal chymoptrypsin.Type: GrantFiled: September 25, 2008Date of Patent: August 30, 2011Assignee: Curemark, LLCInventor: Joan M. Fallon
-
Publication number: 20100233218Abstract: A stable preparation of digestive/pancreatic enzymes which can be readily formed into a dosage formulation is provided as a treatment of pancreatic insufficiency in persons having cystic fibrosis. The dosage formulation can be administered either by an oral preparation including, but not limited to, a microcapsule, mini-capsule, time released capsule, sprinkle or other methodology. A further object of this invention is to provide a stabilized preparation of a combination medicant which resists degradation by light, heat, humidity or association with commonly used excipients.Type: ApplicationFiled: May 25, 2010Publication date: September 16, 2010Applicant: CUREMARK LLCInventor: Joan M. Fallon